Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 11/20 | 0.36 |
| ▸ | CNR1 | P21554 | 9/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256875 | 0.84 | TDP1 (0.34) | CNR2CNR1GRM4 | |
| SCHEMBL19257092 | 0.84 | GRM4 (0.34) | CNR2CNR1GRM4 | |
| SCHEMBL803133 | 0.80 | CYP2A6 (0.50) | CYP2A6PRMT3PDE3BPDE3A | |
| SCHEMBL19863918 | 0.74 | UHRF1 (0.42) | CNR2CNR1ESR1ARESR2 | |
| SCHEMBL24147138 | 0.72 | TDP1 (0.42) | GRM4 | |
| SCHEMBL14035943 | 0.72 | ROCK1 (0.53) | — | |
| SCHEMBL23386421 | 0.72 | CNR1 (0.42) | CNR2CNR1PRMT3 | |
| SCHEMBL19256867 | 0.72 | MAPK1 (0.37) | CNR2CNR1ESR1ARESR2 | |
| SCHEMBL12316027 | 0.72 | CNR2 (0.42) | CNR2CNR1ESR1ARESR2 | |
| SCHEMBL19256974 | 0.72 | CNR1 (0.41) | CNR2CNR1ESR1ARESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233381-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | CYP2A6 2488/4885CNR2 1434/4885CNR1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.